| Literature DB >> 30171743 |
Ghazaleh Rafatian1, Darryl R Davis1.
Abstract
Despite progress in cardiovascular medicine, the incidence of heart failure is rising and represents a growing challenge. To address this, ex vivo proliferated heart-derived cell products have emerged as a promising investigational cell-treatment option. Despite being originally proposed as a straightforward myocyte replacement strategy, emerging evidence has shown that cell-mediated gains in cardiac function are leveraged on paracrine stimulation of endogenous repair and tissue salvage. In this concise review, we focus on the paracrine repertoire of heart-derived cells and outline strategies used to boost cell potency by targeting cytokines, metabolic preconditioning and supportive biomaterials. Mechanistic insights from these studies will shape future efforts to use defined factors and/or synthetic cell approaches to help the millions of patients worldwide suffering from heart failure. Stem Cells 2018;36:1794-10. © AlphaMed Press 2018.Entities:
Keywords: Adult stem cells; Cardiac; Cellular therapy; Insulin-like growth factors; Somatic cell; Stromal-derived factor-1; Therapy
Mesh:
Year: 2018 PMID: 30171743 DOI: 10.1002/stem.2910
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277